New blood test could prevent dangerous delays in preeclampsia deliveries

NCT ID NCT07665112

Not yet recruiting Disease control Sponsor: Hospital Clinic of Barcelona Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a blood test measuring the sFlt-1/PlGF ratio can help doctors decide the best time to deliver babies in women with severe early-onset preeclampsia. The trial will include 386 pregnant women between 30 and 34 weeks of gestation. Half will have delivery timing guided by the test results, while the other half will receive standard care. The goal is to reduce serious complications for both mothers and newborns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sFlt-1/PlGF ratio blood test
What this could lead to: If successful, this blood test could help doctors decide the safest time to deliver in severe preeclampsia, reducing serious complications for both mother and baby.
What could go wrong: This is an early-stage trial with 386 participants, so results may not apply to all cases. The test may not improve outcomes as hoped, and timing decisions still carry risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE PREECLAMPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia severe pre-eclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE PREECLAMPSIA

Contacts and locations

Locations

c/ Sabino Arana, 1. 08028 Barcelona

Barcelona, Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.